Regulatory T Cells: What the Nobel Discovery Means

What keeps the immune system from attacking the body?

Your immune system needs to respond to threats. It also needs ways to hold that response in check. Regulatory T cells, usually called Tregs, are part of that control system.

The 2025 Nobel Prize in Physiology or Medicine recognised Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi for discoveries about peripheral immune tolerance: how immune responses are controlled outside the organs where immune cells first develop. Their work helps explain why the body usually avoids attacking itself. [1]

For someone living with autoimmune disease, the practical question is what those discoveries have led to. There are human trials worth understanding, including encouraging results and studies where changing immune cells did not improve the main clinical outcome.

How the pieces came together

In 1995, Sakaguchi and colleagues showed that removing a group of CD4-positive, CD25-positive T cells allowed autoimmune disease to develop in a mouse transfer experiment. Adding those cells back within a limited time helped prevent it. This was evidence for an active system of immune restraint. It was a mouse experiment, not a treatment trial in people. [2]

In 2001, Brunkow, Ramsdell and colleagues identified a defect in the Foxp3 gene in scurfy mice, which develop severe immune dysfunction. Human genetic work linked mutations in FOXP3 to IPEX, a rare syndrome involving immune dysregulation. These findings connected a specific gene with the loss of immune control. [3] [4]

Work published in 2003 then showed that Foxp3 helps direct the development of regulatory T cells. Think of it as part of the instructions that allow these cells to do their job. That explains a mechanism; it does not tell us which treatment will help a particular person. [5]

What have low-dose IL-2 trials found in lupus?

Interleukin-2, or IL-2, is an immune signalling protein. Researchers have tested low doses to increase Tregs in people with systemic lupus erythematosus, alongside their usual treatment. The results depend on the trial, the schedule and the outcome being measured.

A 60-person randomized trial published in 2020 did not meet its main outcome at week 12. The lupus response rates were about 55% with IL-2 and 30% with placebo, but that difference fell short of the study's statistical threshold. A difference appeared at week 24. A small subgroup with lupus nephritis also had more complete kidney remissions with IL-2. Those later and subgroup findings are useful signals, but they do not change the missed primary outcome. [6]

The 100-person LUPIL-2 trial also missed its primary outcome: 68% versus 58% met the response criteria at week 12. A later analysis excluding two study sites favoured IL-2. That exclusion makes the positive finding less conclusive than success in the original randomized comparison. [7]

A 2026 phase IIb trial adds a more encouraging result. It randomized 152 people across three IL-2 groups and placebo. The authors reported higher week-12 response rates in the two higher-dose groups, alongside Treg expansion. Its main efficacy analysis excluded participants who discontinued or lacked outcome data, with an additional analysis reported as consistent. Follow-up lasted 24 weeks. Injection-site reactions occurred, and the authors noted that many mild possible COVID infections were not recorded as adverse events. Longer-term benefit and safety still need study. [8]

Type 1 diabetes shows why the clinical outcome matters

Researchers have also tried collecting a person's Tregs, expanding them outside the body and returning them by infusion. The small TILT study combined this approach with low-dose IL-2 in nine people with type 1 diabetes. Tregs increased, but so did some activated NK and other potentially cell-killing immune populations. The study did not show improved islet metabolic function. Its open-label design and small size limit what it can establish. [9]

A larger trial published in October 2026 makes the distinction especially clear. DIABIL-2 randomized 141 people with newly diagnosed type 1 diabetes to two low-dose IL-2 schedules or placebo. Tregs increased, but IL-2 did not preserve beta-cell function at 12 months on the primary C-peptide measure, which reflects the body's own insulin production. Serious adverse events occurred in both treatment and placebo groups; one in each group was considered probably treatment-related. [10]

That is why a headline about increasing Tregs needs a second question: did the people in the trial experience the intended benefit?

Where do MSCs fit into this?

Tregs and mesenchymal stromal cells, or MSCs, are different cell types. The connection is an area of research into immune modulation, meaning changes in how immune responses are regulated.

A 2010 single-arm study followed 16 people with severe or treatment-resistant lupus after umbilical-cord MSC transplantation. The investigators reported improved disease measures alongside increased circulating Tregs. Without a control group, the study cannot establish how much of the improvement came from the cells or whether the Treg change caused it. [11]

The Nobel-recognised discoveries provide a reason to investigate these pathways. They do not establish the effectiveness of an MSC product, an infusion protocol or a treatment offered by a clinic.

Our guide to reading a regenerative medicine study walks through those questions. You can also find the trial records in the Science research library.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. The studies describe specific research settings and do not establish which treatment is appropriate for an individual. Any treatment decision should be made with a qualified physician. Individual results vary.